Latest News for: vegf

Edit

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to ...

The Ridgway Record 16 Feb 2026
CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has ...
Edit

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

PR Newswire 16 Feb 2026
CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S ... SUZHOU, China, Feb. 15, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX ... About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody).
Edit

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific ...

Nasdaq Globe Newswire 05 Jan 2026
CR-001 IND cleared by U.S.
Edit

Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"

PR Newswire 10 Nov 2025
Tosposertib (TU2218) is a highly potent, oral dual inhibitor designed to block the signaling pathways of transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), two critical mediators of tumor growth and metastasis.
  • 1

Article Search

tools
×
×
×
×